ESMO 2024: Treatment of uHCC - Episode 4

Use of monotherapy (IO or TKI) or localized treatment in First Line

October 18, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP. 2: Treatment Decisions Based on BLCL Stage

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

Now Viewing

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

Video content above is prompted by the following:

When would you choose monotherapy with either a tyrosine kinase inhibitor or immunotherapy?